The 12 analysts offering 12-month price forecasts for Mirati Therapeutics Inc have a median target of 212.00, with a high estimate of 300.00 and a low estimate of 171.00. The median estimate represents a +60.02% increase from the last price of 132.48.
The current consensus among 16 polled investment analysts is to Buy stock in Mirati Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.99
Reporting Date Mar 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.